Abstract: A tGal-3BP-Fc fusion protein, a pharmaceutical composition, an isolated nucleic acid, a recombinant expression vector, and a method of inhibiting, decreasing, reducing, suppressing or limiting metastasis of cancer cells, and immunosuppressing or modulating phagocytosis and T-cell functions by using the same are disclosed herein. The tGal-3BP-Fc fusion protein comprises: a truncated Gal-3 binding protein with domain 4, and at least an Fc fragment of an immunoglobulin G. A pharmaceutical composition comprises the tGal-3BP-Fc or Fc-tGal-3BP fusion protein, and a pharmaceutically acceptable carrier. The method comprises a step of administrating the pharmaceutical composition to a subject in a therapeutically effective amount to inhibit, decrease, reduce, suppress or limit invasiveness and metastasis of cancer cells or to treat or modulate immune reactions of inflammatory diseases in the subject.